Ainos, Inc.

NasdaqCM:AIMD 株式レポート

時価総額:US$3.7m

Ainos 過去の業績

過去 基準チェック /06

Ainos's earnings have been declining at an average annual rate of -49.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 43.2% per year.

主要情報

-49.6%

収益成長率

-5.4%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率43.2%
株主資本利益率-74.4%
ネット・マージン-23,663.6%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

Mar 10
We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Aug 28
Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

May 15
Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Sep 30

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Aug 24

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Aug 15

収支内訳

Ainos の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqCM:AIMD 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 240-1568
31 Mar 240-1567
31 Dec 230-1467
30 Sep 231-1037
30 Jun 233-1597
31 Mar 233-1497
31 Dec 224-1497
30 Sep 223-1386
30 Jun 221-725
31 Mar 221-523
31 Dec 211-422
30 Sep 211-331
30 Jun 210-220
31 Mar 210-220
31 Dec 200-110
30 Sep 200-110
30 Jun 200-110
31 Mar 200-220
31 Dec 190-220
30 Sep 190-220
30 Jun 190-220
31 Mar 190-220
31 Dec 180-110
30 Sep 180-110
30 Jun 180-110
31 Mar 180-110
31 Dec 170-110
30 Sep 170-110
30 Jun 170-110
31 Mar 170-110
31 Dec 160-110
30 Sep 160-110
30 Jun 160-110
31 Mar 160-110
31 Dec 150-110
30 Sep 150300
30 Jun 150300
31 Mar 150300
31 Dec 140300
30 Sep 140-110
30 Jun 140-110
31 Mar 140-100

質の高い収益: AIMD is currently unprofitable.

利益率の向上: AIMD is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: AIMD is unprofitable, and losses have increased over the past 5 years at a rate of 49.6% per year.

成長の加速: Unable to compare AIMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: AIMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


株主資本利益率

高いROE: AIMD has a negative Return on Equity (-74.4%), as it is currently unprofitable.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘